Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592391 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL4863174 | 0.95 | SMN1; SMN2 (0.67) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL1788188 | 0.89 | NOTUM (0.68) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1MAPT | |
| SCHEMBL31414988 | 0.89 | NOTUM (0.68) | SMN1; SMN2NOTUMSIGMAR1ALDH1A1MAPT | |
| SCHEMBL11551817 | 0.86 | SMN1; SMN2 (0.81) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL4019697 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL29353444 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL4291340 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL2829456 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL8823905 | 0.83 | TSHR (0.56) | SMN1; SMN2NOTUMALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| CN-113816902-B | Oxime ether (ester) compound, preparation method and application | 西北农林科技大学 | 2023-09-01 | — | — | CN | disclosed |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| CN-113816902-A | Oxime ether (ester) compound, preparation method and application | 西北农林科技大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| WO-2019185046-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | 上海美悦生物科技发展有限公司 | 2019-10-03 | — | — | WO | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5654257-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1997-08-05 | — | — | US | disclosed |
| US-5650374-A | PREEMERGENCE OR POSTEMERGENCE HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0728750-A1 | 1-Cycloalkenyltetrazolinones | NIHON BAYER AGROCHEM K.K. (JP) | 1996-08-28 | — | — | EP | disclosed |
| EP-0712850-A1 | Herbicidal novel 1-cyclopropyl tetrazolinones | NIHON BAYER AGROCHEM K.K. (JP) | 1996-05-22 | — | — | EP | disclosed |
| US-5478845-A | Inhibit dopamine or 5-hydroxytryptamine receptor binding | NOVO NORDISK A/S (DK) | 1995-12-26 | — | — | US | disclosed |
| US-5312820-A | Angiotensin antagonist for treatment of hypertension | MERCK & CO., INC. (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0423679-B1 | Process for the preparation of 5-(carbamoyl)-5H-dibenz[b,f]azepines | ALKALOIDA VEGYESZETI GYAR (HU) | 1994-04-27 | — | — | EP | disclosed |
| US-4973588-A | IMPROVED BRAIN FUNCTION AT REDUCED OXYGEN LEVELS | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-11-27 | — | — | US | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | SMN1; SMN2 3634/4885NOTUM 4338/4885SIGMAR1 146/4885 |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | SMN1; SMN2 3283/4885NOTUM 106/4885SIGMAR1 4372/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | SMN1; SMN2 3283/4885NOTUM 106/4885SIGMAR1 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.